Natural human immunoglobulins in cancer immunotherapy

Immunotherapy
H Peter Vollmers, Stephanie Brändlein

Abstract

The natural or innate immunity is the first-line defense against transformed cells. It guarantees the recognition and removal of malignant cells at an early stage and makes manifest cancers an exceptional event. Natural antibodies, which are predominantly IgM molecules, play a major role in these defense mechanisms and they have some typical features in common. They are coded by specific germline families and equipped mainly with lambda-chains, in contrast to the majority of circulating antibodies. The targets that are recognized by these antibodies are not newly synthesized proteins, but instead post-translationally modified carbohydrate structures on membrane-bound glycoproteins and glycolipids. Another typical feature of these natural IgM antibodies is their ability to induce apoptosis in vitro and in vivo in a death domain-independent manner. These results show that natural IgM antibodies represent a huge reservoir of therapeutic antibodies.

References

Apr 1, 1988·The Journal of Clinical Investigation·N K CheungM E Medof
Nov 1, 1989·Immunology Today·P Casali, A L Notkins
Jun 15, 1989·Cancer·M J Wizenberg
Aug 15, 1995·Cancer·H P VollmersH K Müller-Hermelink
Apr 3, 1999·International Journal of Cancer. Journal International Du Cancer·F HenselH P Vollmers
Apr 7, 2000·Breast Cancer Research and Treatment·P M FernandezS R Patierno
Jun 3, 2000·Archives of Pathology & Laboratory Medicine·G G Klee
Aug 15, 2001·Laboratory Investigation; a Journal of Technical Methods and Pathology·F HenselH P Vollmers
Nov 14, 2001·Laboratory Investigation; a Journal of Technical Methods and Pathology·F HenselH P Vollmers
Mar 22, 2002·Nature Reviews. Immunology·R Medzhitov
Apr 16, 2002·Science·Ruslan Medzhitov, Charles A Janeway
May 2, 2003·Nature·Peter Parham
Dec 2, 2004·Nature Reviews. Cancer·Yanjun Ma, Linda M Hendershot
Feb 9, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Uma Kant MisraSalvatore Vincent Pizzo
Jun 4, 2005·Advances in Experimental Medicine and Biology·Chandrashekhar Pasare, Ruslan Medzhitov
Jun 14, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Hidetaka UramotoKosei Yasumoto
Oct 7, 2005·The New England Journal of Medicine·Alberto J L Macario, Everly Conway de Macario
Oct 8, 2005·Oncology·Stefanie Schier, Nicholas A Wright
Feb 14, 2006·Current Molecular Medicine·Jianze Li, Amy S Lee
Feb 14, 2006·Current Molecular Medicine·Constantinos Koumenis
Feb 18, 2006·Cancer Immunology, Immunotherapy : CII·Ian SpendloveLindy G Durrant
Feb 25, 2006·Cell·Shizuo AkiraOsamu Takeuchi
Feb 25, 2006·Cell·Max D Cooper, Matthew N Alder
Mar 29, 2006·Melanoma Research·James M G LarkinColin D Porter
May 6, 2006·The Journal of Allergy and Clinical Immunology·Tsuneyasu Kaisho, Shizuo Akira

❮ Previous
Next ❯

Citations

Jul 5, 2011·Medical Hypotheses·Leodevico L Ilag
Mar 10, 2015·Biochimica Et Biophysica Acta·Veronika ChromikovaRenate Kunert

❮ Previous
Next ❯

Methods Mentioned

BETA
protein folding
glycosylation
xenograft
surgical resection
biopsy

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis